The Clalit Research Institute is currently examining the effect of the vaccine against the coronavirus developed by Pfizer. Preliminary data show that 14 days after the injection of the first vaccine, there is a real decrease in the rate of infection in the corona . The study compared the infection data of about 200,000 people aged 60 and over who
As of January 20, 2021, a total of 24,135,690 cases of coronavirus disease 2019 (COVID-19) and 400,306 associated deaths had been reported in the United States (https://covid.cdc.gov/covid-data-tracker/#cases_casesper100klast7days). On December 18, 2020, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for Moderna COVID-19 vaccine administered as 2 doses, 1 month apart to
Scientists at Children’s Hospital Los Angeles develop newer CAR T therapy that promises to be more effective and less toxic for children with neuroblastoma. Chimeric Antigen Receptor T-cell therapy—CAR T—has revolutionized leukemia treatment. Unfortunately, the therapy has not been effective for treating solid tumors including childhood cancers such as neuroblastoma. Preclinical studies using certain CAR
Following implementation of vaccination, reports of anaphylaxis after the first dose of the Pfizer-BioNTech COVID-19 vaccine emerged.Anaphylaxis is a life-threatening allergic reaction that occurs rarelyafter vaccination, with onset typically within minutes to hours.Notifications and reports of suspected severe allergic reactions and anaphylaxis following vaccination were captured in the Vaccine Adverse Event Reporting System (VAERS), the
Researchers in Cedars-Sinai Medical Center, Los Angeles found that the variant, originated in California, was present in more than half of samples tested last week by researchers in Los Angeles. In late December, scientists in California began searching coronavirus samples for a fast-spreading new variant that had just been identified in Britain. They found it, though in
The increased prevalence of obesity, diabetes and cardiovascular risk factors in people hospitalized with severe COVID-19 illness has engendered considerable interest in the metabolic aspects of SARS-CoV-2-induced pathophysiology. In this paper published in Cell Metabolism are updated concepts informing how metabolic disorders and their comorbidities modify the susceptibility to, natural history and potential treatment of
Virus-specific humoral and cellular immunity act synergistically to protect the host from viral infection. In this paper published on Cell Reports are interrogated the dynamic changes of virological and immunological parameters in 12 patients with symptomatic acute SARS-CoV-2 infection from disease onset to convalescence or death. SARS-CoV-2 viral RNA in the respiratory tract in parallel
Evidence is growing that self-attacking ‘autoantibodies’ could be the key to understanding some of the worst cases of SARS-CoV-2 infection. More than a year after COVID-19 emerged, many mysteries persist about the disease: why do some people get so much sicker than others? Why does lung damage sometimes continue to worsen well after the body
A new study found that antibodies in patients vaccinated against COVID-19 were able to neutralize a version of the new variant. Researchers tested 10 mutations of the B117 variant, which was first identified in the UK. The COVID-19 vaccine developed by BioNTech and Pfizer is likely to protect against the highly infectious variant of the virus, originally found
No definitive treatment for COVID-19 exists although promising results have been reported with remdesivir and glucocorticoids. Short of a truly effective preventive or curative vaccine against SARS-CoV-2, it is becoming increasingly clear that multiple pathophysiologic processes seen with COVID-19 as well as SARS-CoV-2 itself should be targeted. Because alpha-1-antitrypsin (AAT) embraces a panoply of biologic
